Header cover image
  • Investing Ideas
  • Hong Kong Pharmaceuticals & Biotech High Return On Equity, Low Debt

Hong Kong Pharmaceuticals & Biotech High Return On Equity, Low Debt

Results

1

0 new

Stocks with a return on equity of over 30% and a debt to equity ratio below 1.

1 companies

RemeGen

Market Cap: HK$68.2b

A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

9995

HK$78.90

7D

-2.2%

1Y

-2.7%